Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Gains from Sales and Divestitures (2011 - 2025)

Pediatrix Medical (MD) reported Gains from Sales and Divestitures of $841425.0 for Q4 2025, down 14.8% year-over-year from $987593.0 in Q4 2024, and down 14.8% on a QoQ basis from $987593.0 in Q4 2024.

Pediatrix Medical (MD) has 13 years of Gains from Sales and Divestitures data on file, last reported at $841425.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 14.8% year-over-year to $841425.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $841425.0 (down 14.8% YoY) and the FY2025 annual result came in at $841425.0, down 14.8% from the prior year.
  • Gains from Sales and Divestitures eased to $841425.0 in Q4 2025 per MD's latest filing, from $987593.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $987593.0 in Q4 2024 and bottomed at $418756.0 in Q4 2023.
  • The 5-year median for Gains from Sales and Divestitures is $748410.0 (2021), against an average of $745246.8.
  • The widest annual swing landed in 2023, when Gains from Sales and Divestitures sank 42.64%; it then surged 135.84% in 2024.
  • Tracing MD's Gains from Sales and Divestitures over 5 years: stood at $748410.0 in 2021, then retreated by 2.45% to $730050.0 in 2022, then slumped by 42.64% to $418756.0 in 2023, then surged by 135.84% to $987593.0 in 2024, then decreased by 14.8% to $841425.0 in 2025.
  • Per Business Quant, the three latest MD Gains from Sales and Divestitures figures stand at $841425.0 (Q4 2025), $987593.0 (Q4 2024), and $418756.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Pediatrix Medical 1.74 Bn 1.41 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 841,425.00
Dec 31, 2025 841,425.00
Dec 31, 2024 987,593.00
Dec 31, 2024 987,593.00
Dec 31, 2023 418,756.00
Dec 31, 2023 418,756.00
Dec 31, 2022 730,050.00
Dec 31, 2022 730,050.00
Dec 31, 2021 748,410.00
Dec 31, 2021 748,410.00
Dec 31, 2018 431,368.00
Dec 31, 2018 431,368.00
Dec 31, 2017 451,094.00
Dec 31, 2017 451,094.00
Dec 31, 2016 519,448.00
Dec 31, 2016 519,448.00
Dec 31, 2015 710,702.00
Dec 31, 2015 710,702.00
Sep 30, 2015 18,282.00
Sep 30, 2015 18,282.00
Dec 31, 2014 744,794.00
Dec 31, 2014 744,794.00
Dec 31, 2013 1.05 Mn
Dec 31, 2013 1.05 Mn
Dec 31, 2012 423,331.00
Dec 31, 2012 423,331.00
Dec 31, 2011 388,969.00
Dec 31, 2011 388,969.00